Premium
Paediatric cancer survivors demonstrate a high rate of subclinical renal dysfunction
Author(s) -
Mudi Abdullahi,
Levy Cecil Steven,
Geel Jennifer Ann,
Poole Janet Elizabeth
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26132
Subject(s) - medicine , renal function , proteinuria , subclinical infection , nephrology , urology , cancer , tubulopathy , gastroenterology , kidney
Background Clinical manifestations of renal dysfunction in childhood cancer survivors include hypertension, proteinuria, tubulopathy (and its biochemical consequences) and renal insufficiency. This study aimed to determine the factors associated with renal dysfunction in paediatric cancer survivors at a single centre in Johannesburg. Procedure A descriptive cross‐sectional study was performed on 130 cancer survivors between 2 and 18 years of age. Physical examination and screening urine dipstick were performed on all patients. Blood results of samples routinely drawn were analysed. Results After a median follow‐up period of 2 years, the various manifestations of renal dysfunction included decreased estimated glomerular filtration rate (eGFR), hypomagnesaemia, hypophosphataemia, proteinuria, haematuria and hypertension. In total, 34 survivors (26.15%) had at least one manifestation of renal dysfunction after completing treatment. The most prevalent manifestation of renal dysfunction was decreased eGFR (17.7%) followed by hypomagnesaemia (6.2%) and hypophosphataemia (4.6%). Patients with pre‐existing renal dysfunction were three times more likely to have renal dysfunction post‐treatment ( P = 0.020). Ifosfamide ( P = 0.010) and nephrectomy ( P = 0.003) had independent significant impact on reduction in eGFR. High cumulative ifosfamide doses were identified as a possible cause for hypophosphataemia ( P = 0.021). Conclusion While not clinically evident in the early follow‐up period, the high rate of renal dysfunction is concerning. We suggest that patients with pre‐existing renal dysfunction should be assessed by a nephrologist prior to initiation of cancer therapy, and nephro‐protective measures should be employed stringently in all children with cancer. Patients with decreased eGFR should be followed up closely in a multidisciplinary late effects clinic.